文献速递肥胖与代谢综合征

剪接机制失调与非酒精性脂肪性肝病发生相关

Dysregulation of the Splicing Machinery Is Associated to the Development of Nonalcoholic Fatty Liver Disease.
PubMed 文献 · J Clin Endocrinol Metab · 2019-01-01

该研究分析41例接受减重手术的肥胖患者肝活检,用微流控定量PCR阵列检测剪接机制组分表达;发现伴脂肪变者肝内剪接组分严重失调,可分三种分子表型并对应不同临床代谢特征及术后1年反应;体外沉默PTBP1、RBM45、SND1可减少HepG2细胞脂肪积累。

要点

  • 肥胖伴肝脂肪变患者肝内剪接机制组分表达严重失调。
  • 无监督聚类可识别三种NAFLD分子表型,与肝及临床代谢改变相关。
  • 体外沉默PTBP1、RBM45、SND1可减少脂肪积累并调节脂肪生成酶。

核心结论

  • 剪接机制失调与NAFLD发生存在密切关系,值得进一步研究以寻找替代治疗靶点。

研究设计与样本

  • 收集41例接受减重手术的非酒精性肥胖个体肝活检,按有无肝脂肪变分组。
  • 用微流控定量PCR阵列检测剪接机制组分表达,并行HepG2细胞体外脂质积累实验。

主要发现

  • 与无脂肪变的肥胖患者相比,伴脂肪变者肝内特定剪接机制组分严重失调。
  • 无监督聚类识别出三种NAFLD分子表型,各具独特剪接组分改变指纹及不同肝与临床代谢改变。
  • 三种分子表型对减重术后1年反应不同。
  • 体外沉默PTBP1、RBM45或SND1可减少脂肪积累并调节关键从头脂肪生成酶表达。
  • 相反,脂肪积累未改变剪接体组分表达。

临床怎么用

  • 剪接机制组分表达谱可能用于区分肥胖患者NAFLD分子表型并预测减重手术反应。
  • PTBP1、RBM45、SND1等剪接组分是潜在干预靶点,但尚需进一步验证。

局限性

  • 样本为接受减重手术的肥胖患者肝活检,共41例,结论外推需谨慎。
  • 剪接机制与NAFLD的因果关系及治疗靶点价值仍需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Nonalcoholic fatty liver disease (NAFLD) is a common obesity-associated pathology characterized by hepatic fat accumulation, which can progress to fibrosis, cirrhosis, and hepatocellular carcinoma. Obesity is associated with profound changes in gene-expression patterns of the liver, which could contribute to the onset of comorbidities. OBJECTIVE: As these alterations might be linked to a dysregulation of the splicing process, we aimed to determine whether the dysregulation in the expression of splicing machinery components could be associated with NAFLD. PARTICIPANTS: We collected 41 liver biopsies from nonalcoholic individuals with obesity, with or without hepatic steatosis, who underwent bariatric surgery. INTERVENTIONS: The expression pattern of splicing machinery components was determined using a microfluidic quantitative PCR-based array. An in vitro approximation to determine lipid accumulation using HepG2 cells was also implemented. RESULTS: The liver of patients with obesity and steatosis exhibited a severe dysregulation of certain splicing machinery components compared with patients with obesity without steatosis. Nonsupervised clustering analysis allowed the identification of three molecular phenotypes of NAFLD with a unique fingerprint of alterations in splicing machinery components, which also presented distinctive hepatic and clinical-metabolic alterations and a differential response to bariatric surgery after 1 year. In addition, in vitro silencing of certain splicing machinery components (i.e., PTBP1, RBM45, SND1) reduced fat accumulation and modulated the expression of key de novo lipogenesis enzymes, whereas conversely, fat accumulation did not alter spliceosome components expression. CONCLUSION: There is a close relationship between splicing machinery dysregulation and NAFLD development, which should be further investigated to identify alternative therapeutic targets.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Del Río-Moreno M, Alors-Pérez E, González-Rubio S, et al. Dysregulation of the Splicing Machinery Is Associated to the Development of Nonalcoholic Fatty Liver Disease. J Clin Endocrinol Metab. 2019. PMID: 30901032. doi:10.1210/jc.2019-00021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。